Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 10,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kind Clear all
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 28, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

NCT00845039
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and metformin, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 28, 2026, 1:04 AM EDT
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System

NCT02041286
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi Contour Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 1:04 AM EDT
Terminated No phase listed Observational

Mesothelioma Early Detection by VOCs

NCT04106973
View directory record Official record
Conditions
Pleural Mesothelioma, Asbestos Exposure, Pleural Plaque
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

NCT00266253
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Placebo Controlled Trial of Botulinum Toxin for Gastroparesis

NCT00372970
View directory record Official record
Conditions
Gastroparesis
Interventions
Botulinum toxin A, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Oct 28, 2026, 1:04 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

NCT05467670
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, ALX148, Doxorubicin
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

NCT01607294
View directory record Official record
Conditions
Hyperlipidemia, Type 2 Diabetes
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 28, 2026, 1:04 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease

NCT04055831
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
Not listed
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
16 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-Level Approach to Heat-Related Illness Prevention in Agricultural Workers

NCT04234802
View directory record Official record
Conditions
Heat Stress Disorders
Interventions
Heat Education and Awareness Tools
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 28, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients

NCT06663813
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
Educational Intervention
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Combined Treatment for Alcohol-Dependent Individuals With PTSD

NCT00262223
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions
Seeking Safety, Sertraline, Pill placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 28, 2026, 1:04 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Quality Initiative to Improve Glucose Control in Type 2 Diabetic Patients

NCT03705260
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Usual Care, Intensive Behavioral Intervention, Monthly Screening for Risk
Other · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chelsea, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 28, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

NCT04093323
View directory record Official record
Conditions
HLA-A2 Positive Cells Present, Refractory Melanoma
Interventions
Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 1:04 AM EDT
Completed No phase listed Observational

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

NCT00717223
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Glucose Meter Study

NCT00782496
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Education + new meter, Education + new meter + feature activation
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
21 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Preprandial Ghrelin Effect

NCT02913703
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Ghrelin, Saline
Drug · Other
Lead sponsor
Jenny Tong, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 28, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes

NCT04461405
View directory record Official record
Conditions
Type II Diabetes, Primary Health Care, Behavioral Health
Interventions
INTEGRATE-D
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 28, 2026, 1:04 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

NCT04860960
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Oakland, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 28, 2026, 1:04 AM EDT